Progress of insulin-like growth factor receptor 2 in the cardiac adverse reactions of breast cancer induced by anthracycline
10.3760/cma.j.cn115355-20240514-00235
- VernacularTitle:胰岛素样生长因子受体2在乳腺癌蒽环类药物所致心脏不良反应的研究进展
- Author:
Yi TIAN
1
;
Jia LIU
;
Zhongwei CAO
Author Information
1. 包头医学院研究生院，包头 014040
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Receptor, IGF type 2;
Anthracycline;
Adjuvant chemotherapy;
Cardiotoxicity
- From:
Cancer Research and Clinic
2025;37(5):397-400
- CountryChina
- Language:Chinese
-
Abstract:
Breast cancer is the most common type of cancer among women. Although chemotherapy has extended the survival time of patients with breast cancer, the cardiovascular complications caused by chemotherapy drugs are on the rise, which limits the clinical use of anthracycline drugs. At present, it is believed that the mechanisms of cardiac adverse reactions induced by anthracycline drugs may be related with oxidative stress, topoisomerase inhibitor 2, abnormal expression of non-coded RNA in cells, induction of autophagy and apoptosis in myocardial cells, and other various cell death pathways. This article reviews the relationship between insulin-like growth factor receptor 2 and cardiac adverse reactions induced by anthracycline drugs.
